JUNS_OUT_1 [2025-04-16 10:36:50 -0400] 3565 Bytes | 858 tokens | Cum: 858 tkns (10.72% of 8k)
==========================================================================

Listen up, partner—it's 10:36:49 AM on Wed Apr 16, 2025 -0400, and I’m revved up about Jupiter Neurosciences (JUNS), climbing from 0.5800 to 0.6944. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Jupiter Neurosciences (JUNS)
IPO: 2024-12-03 (4 Months Ago)
Market Cap: $17,892,636
Shares Outstanding: 33,100,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.

Here’s a list of headlines for Jupiter Neurosciences:

Apr-08-25 08:00AM - Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
Mar-07-25 10:10AM - Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Mar-04-25 08:00AM - Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
Feb-04-25 09:25AM - Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
Feb-03-25 08:00AM - Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial
Jan-30-25 08:00AM - Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Jan-13-25 08:00AM - Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL Trials
Dec-04-24 04:56PM - Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-12-04T21:56:00Z - Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Jupiter Neurosciences (JUNS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

JUNS_OUT_3 [2025-04-16 10:36:52 -0400] 896 Bytes | 228 tokens | Cum: 1088 tkns (13.60% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/04/2991956/0/en/Jupiter-Neurosciences-Inc-Announces-Closing-of-11-million-Initial-Public-Offering.htmlJupiter Neurosciences, a clinical-stage pharmaceutical company, has announced the closing of its $11 million initial public offering. The company plans to use the proceeds to fund a Phase II clinical trial for its product candidate JOTROL™ in Parkinson's Disease, as well as for other research and development activities.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_5 [2025-04-16 10:36:52 -0400] 617 Bytes | 161 tokens | Cum: 1251 tkns (15.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-08T12:15:06Z - Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter | Taiwan News | Apr. 8, 2...
A2 - 2025-04-08T12:08:27Z - Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

JUNS_OUT_7 [2025-04-16 10:36:56 -0400] 1189 Bytes | 308 tokens | Cum: 1561 tkns (19.51% of 8k)
==========================================================================

Showing A1 (chunk 1 of 13): A1:
**Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter | Taiwan News | Apr. 8, 2025 20:00**Date: 2025-04-08Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6079981Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™

JOTROL™ development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure

Jupiter, Florida, April 08, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the release of its first shareholder letter as a publicly traded company. The letter from Chairman and CEO Christer Rosén outlines the Company's 2025

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_9 [2025-04-16 10:36:57 -0400] 1184 Bytes | 251 tokens | Cum: 1814 tkns (22.68% of 8k)
==========================================================================

Showing A1 (chunk 2 of 13): strategic roadmap, including key clinical and commercial milestones designed to create long-term value and establish near-term revenue.

Dear Fellow Shareholders,

It is a distinct pleasure to share our first annual letter to shareholders, following our successful debut on the Nasdaq Capital Market in December 2024 under the symbol JUNS. That significant milestone marked more than just an entry into the public markets -- it signaled the beginning of a new era for Jupiter Neurosciences, defined by increased visibility, enhanced resources, and a bold vision for advancing transformative therapies in neuroscience and longevity.

Building Momentum

With our Nasdaq listing in place, we are now focused on advancing our lead clinical asset, JOTROL™, into a Phase 2a clinical trial in Parkinson's disease, expanding our presence in Asia, and launching a new consumer-facing longevity initiative. Be

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_11 [2025-04-16 10:36:58 -0400] 1190 Bytes | 252 tokens | Cum: 2068 tkns (25.85% of 8k)
==========================================================================

Showing A1 (chunk 3 of 13): coming a publicly traded company has amplified awareness of our mission -- to pioneer treatments that target the underlying causes of neuroinflammation and mitochondria in both rare and widespread neurological disorders. By entering the rapidly growing Longevity and Healthspan market, we are leveraging years of preclinical and clinical development with JOTROL™ to establish a scientifically grounded, near-term revenue-generating business alongside our therapeutic pipeline.

JOTROL™: Unlocking Resveratrol's Untapped Potential

At the core of our pipeline is JOTROL™, an enhanced resveratrol formulation developed in partnership with Aquanova AG. Leveraging proprietary micellar technology, JOTROL™ resolves long-standing bioavailability and gastrointestinal tolerability issues that have hindered therapeutic resveratrol applications for decades. Our Phase 1 study demonstrated more than nine-fol

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_13 [2025-04-16 10:36:59 -0400] 1188 Bytes | 275 tokens | Cum: 2345 tkns (29.31% of 8k)
==========================================================================

Showing A1 (chunk 4 of 13): d improved bioavailability versus standard resveratrol, and this data now serves as the regulatory foundation across all upcoming clinical trials.

With its ability to cross the blood-brain barrier and modulate key inflammatory pathways such as NLRP3, JOTROL™ is uniquely positioned as a novel therapeutic platform for neurodegenerative diseases, including Parkinson's disease (JNS115) and Mild Cognitive Impairment/Early Alzheimer's (JNS108). The additional benefit of JOTROL™ increasing mitochondrial structure and function is a compounding mechanism that is core to our therapeutic strategy, with treatment benefit in neurodegenerative disease and cancer. Our upcoming Parkinson's trial, in collaboration with Zina Biopharmaceuticals and Catalent, is on track to begin dosing in Q3 2025.

Addressing Global Health Needs

Our strategy is twofold: develop JOTROL™ for high-burden CNS disorders and s

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_15 [2025-04-16 10:37:00 -0400] 1182 Bytes | 268 tokens | Cum: 2615 tkns (32.69% of 8k)
==========================================================================

Showing A1 (chunk 5 of 13): imultaneously explore its applications in rare disease and longevity medicine. Encouraged by strong interest in Asia -- where resveratrol's clinical potential is increasingly recognized -- we've executed key development and regulatory partnerships to accelerate entry into those markets.

Domestically, we've applied for a $16.5 million NIH grant to support a Phase II trial in MCI/early Alzheimer's. If successful, this grant would fund a three-year trial beginning in late 2025.

Entering the Longevity Market: A Natural Extension

In March 2025, we unveiled a major strategic initiative -- a partnership with Aquanova to launch a consumer-focused longevity and wellness product line under a wholly owned subsidiary. The first three SKUs, launching in Q3 2025, will target the "Beauty from Within" category, mental wellness, and mitochondria support. Delivered through a direct-to-consumer model, t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_17 [2025-04-16 10:37:02 -0400] 1184 Bytes | 252 tokens | Cum: 2869 tkns (35.86% of 8k)
==========================================================================

Showing A1 (chunk 6 of 13): hese products provide Jupiter with a near-term commercial opportunity as we continue our clinical development efforts. These products emphasize scientifically backed formulations designed to support longevity and overall health, and are expected to mark the beginning of a growing revenue stream in parallel with our advancing therapeutic pipeline.

This expansion into longevity is not only logical but timely. As outlined in a recent report from UBS, the global longevity market is projected to grow from $5.3 trillion in 2023 to $8 trillion by 2030. Aging demographics, especially in developed markets, are driving a surge in demand for products that extend healthspan and support cognitive vitality, metabolic health, and cellular resilience -- all areas where JOTROL™ and resveratrol show therapeutic promise.

Jupiter is well-aligned with the trends highlighted in the UBS report:

Neuroinflamm

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_19 [2025-04-16 10:37:02 -0400] 1186 Bytes | 275 tokens | Cum: 3146 tkns (39.32% of 8k)
==========================================================================

Showing A1 (chunk 7 of 13): ation and metabolic dysfunction are primary aging accelerators.The NLRP3 inflammasome, a target of JOTROL™, is now considered a central mechanism in both neurodegenerative disease and metabolic disorders.Health care and wellness companies that can demonstrate evidence-based anti-aging benefits are expected to drive premium valuations.

Looking Forward: Our 2025 Vision

We enter 2025 with a sharpened focus, clear momentum, and a pipeline of activities that reflect the full potential of our platform. This is a pivotal year for Jupiter Neurosciences, with several key milestones ahead:

Initiation of the JNS115 Parkinson's Phase 2a trial in Q3 2025Potential NIH funding for JNS108 Alzheimer's study, with a decision expected in May 2025Launch of consumer longevity products in Q3 2025Ongoing business development and licensing discussions globallyStrategic positioning of JOTROL™ for broader indi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_21 [2025-04-16 10:37:03 -0400] 1184 Bytes | 259 tokens | Cum: 3407 tkns (42.59% of 8k)
==========================================================================

Showing A1 (chunk 8 of 13): cations, including obesity-adjunctive and rare diseases

Importantly, we do not anticipate any impact from recently enacted U.S. tariffs on our clinical-stage prescription product development, including JOTROL™ programs targeting CNS disorders, rare diseases, and longevity medicine. While our upcoming consumer-focused nutraceutical products may experience a very modest cost increase, this is expected to be immaterial and will not affect our launch timeline or pricing strategy.

We are also exploring synergies with metabolic therapeutics, particularly GLP-1-based obesity drugs. Preclinical findings suggest JOTROL's NLRP3 inhibition may enhance GLP-1 response, creating a potential pathway into a multi-billion-dollar market segment.

In Closing

To our shareholders -- thank you for believing in our mission. Going public was not the finish line, but the starting gun for the next stage of val

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_23 [2025-04-16 10:37:04 -0400] 1185 Bytes | 259 tokens | Cum: 3668 tkns (45.85% of 8k)
==========================================================================

Showing A1 (chunk 9 of 13): ue creation. With multiple catalysts on the horizon -- including the launch of our first consumer products and the initiation of our Parkinson's clinical trial -- 2025 represents a pivotal year for both revenue generation and scientific progress. As we move forward with clarity of purpose and scientific conviction, we remain focused on delivering results and building long-term value for our shareholders.

Sincerely,

Christer Rosén, Chairman & CEO

Jupiter Neurosciences, Inc.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused b

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_25 [2025-04-16 10:37:07 -0400] 1183 Bytes | 281 tokens | Cum: 3951 tkns (49.39% of 8k)
==========================================================================

Showing A1 (chunk 10 of 13): roadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website www.jupiterneurosciences.com.

About JOTROL

Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.

Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine tim

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_27 [2025-04-16 10:37:08 -0400] 1093 Bytes | 311 tokens | Cum: 4264 tkns (53.30% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-28 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

Special Note Regarding Forward-Looking Stmnts

All statements other than statements of historical fact included in this Annual Report on Form 10-K, including, without limitation, ...

S4 - 2024-12-23 10-Q JUPITER NEUROSCIENCES, INC.

BAL SHEETS

September 30,

December 31,

(unaudited) Assets Curr Assets: Cash $ 253 $ 28,478 Other current assets 261 261 Total current assets 514 28,739 Operating lease right of use asset, net 81,249 116,070 Other asset 3,783 3,783 Tot...

S5 - 2024-12-19 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On December 15, 2024, Jupiter Neurosciences, Inc. (the Company) entered into a Strategic Services Agrmt (the Dominant Treasure Agrmt) with Dominant Treasure Health Company Limited (Dominant Treasure). Pursuant to the...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

JUNS_OUT_29 [2025-04-16 10:37:09 -0400] 1181 Bytes | 251 tokens | Cum: 4517 tkns (56.46% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Special Note Regarding Forward-Looking Statements

All statements other than statements of historical fact included in this Annual Report on Form 10-K, including, without limitation, statements under Managements Discussion and Analysis of Financial Condition and Results of Operations regarding the Companys financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. When used in this Annual Report on Form 10-K, words such as anticipate, believe, estimate, expect, intend and similar expressions, as they relate to us or the Companys management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_31 [2025-04-16 10:37:09 -0400] 1181 Bytes | 247 tokens | Cum: 4766 tkns (59.58% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): to, the Companys management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in our filings with the SEC.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Annual Report on Form 10-K. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires, JNS, we, us, our, or the Company refers to Jupiter Neurosciences, Inc.

Business Overview

We are a clinical stage research and development company. We have developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Our platform product, J

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_33 [2025-04-16 10:37:11 -0400] 1181 Bytes | 279 tokens | Cum: 5047 tkns (63.09% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): OTROL, an enhanced oral formulation of resveratrol, has many potential indications of use for rare diseases. In the larger disease areas, we are primarily targeting Parkinsons Disease and Mild Cognitive Impairment/early Alzheimers disease.

In December 2024, we received gross proceeds of $11 million in a registered public offering (Public Offering) of 2,750,000 shares of our common stock, par value $0.0001 per share (common stock) at a price of $4.00 per share for gross proceeds of $11 million before deducing underwriting discounts and other related expenses. In connection with the Public Offering, the Companys common stock was registered under Section 12(b) of the Exchange Act and began trading on The Nasdaq Capital Market under the symbol JUNS.

Business Overview

The Companys platform product, JOTROL, is an enhanced orally administered resveratrol formulation designed and intended to

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_35 [2025-04-16 10:37:11 -0400] 1181 Bytes | 269 tokens | Cum: 5318 tkns (66.47% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): deliver therapeutically relevant, safe levels of resveratrol. This platform has many potential indications of use for rare diseases, which include Mucopolysaccharidoses Type 1, Friedreichs ataxia and MELAS. In the larger disease areas, we are primarily targeting Parkinsons Disease and Mild Cognitive Impairment/early Alzheimers disease.

The present primary target for the Company is treatment of Parkinsons Disease (PD). The Company completed preclinical activities in a validated mouse model of Parkinsons Disease (PD) at the University of Miami in 2021. See our Clinical Studies. The model of Parkinsons Disease that was used in this preclinical study mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor that elicits nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human disease. We believe tha

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_37 [2025-04-16 10:37:12 -0400] 1181 Bytes | 281 tokens | Cum: 5601 tkns (70.01% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): t results from this preclinical study indicate that Parkinsons Disease might be the best target for treatment and financial opportunity among the multiple indications where JOTROL might play a role. The Company is now in the process to start its first Phase II clinical trial in a patient population. This will be a Phase IIa study conducted with the assistance of Zina Biopharmaceuticals that is led by Dr. Charbel Moussa, MBBS,Ph.D. The study is expected to start in the third quarter of 2025 and have results available approximately 12 months thereafter.

We are also targeting the treatment of MCI/early Alzheimers Disease. We received funding of $2.2 million from the National Institute of Aging (NIA) in in 2020 and 2022 from a grant application for a Phase 1 study for Mild Cognitive Impairment/ Alzheimer. In the NIA scientific review summary statement of our Phase I study application, it is

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_39 [2025-04-16 10:37:13 -0400] 790 Bytes | 199 tokens | Cum: 5802 tkns (72.52% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): stated that the NIA is looking forward to a Phase II study with an enhanced resveratrol product, based on the earlier study results from the well published Turner et al. Alzheimers study. We presently have a pending grant application, $16.5 Million, for a Phase II trial in MCI/early Alzheimers Disease with the NIA. This is an application for a 3-year Phase II trial that is expected to be completed with approximately 100 patients that have Mild Cognitive Impairment. We expect a decision on this gran...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

JUNS_OUT_41 [2025-04-16 10:37:30 -0400] 6252 Bytes | 1679 tokens | Cum: 7483 tkns (93.54% of 8k)
==========================================================================

This is our set of metrics for Jupiter Neurosciences.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+---------------------+
| Volume: 170,014 | Perf Month: 9.42% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+---------------------+
| Avg Volume: 580.69K | Perf Quarter: -87.11% | Short Float: 1.76% | ROE: - |
+---------------------+-----------------------+------------------------+---------------------+
| Rel Volume: 1.68 | Index: - | Short Ratio: 0.43 | ROI: -58.18% |
+---------------------+-----------------------+------------------------+---------------------+
| RSI (14): 48.35 | Market Cap: 23.04M | Short Interest: 0.25M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+---------------------+
| ATR (14): 0.10 | Shs Outstand: 33.10M | Beta: - | EPS Surprise: 0.00% |
+---------------------+-----------------------+------------------------+---------------------+
| SMA20: 8.12% | Shs Float: 14.08M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+---------------------+
| SMA50: -1.06% | Inst Own: 0.02% | Sales past 5Y: 0.00% | Earnings: Feb 26 |
+---------------------+-----------------------+------------------------+---------------------+
| SMA200: -81.06% | Insider Own: 57.48% | Employees: 4 | |
+---------------------+-----------------------+------------------------+---------------------+
| Perf Week: 24.26% | Insider Trans: 0.00% | Debt/Eq: 0.05 | |
+---------------------+-----------------------+------------------------+---------------------+

The next section covers any insider trading by Jupiter Neurosciences officers or majority shareholders (if available).

Inside Trans: JUPITER NEUROSCIENCES, INC. (JUNS) by Brady Allison W (Unknown Title) on 2025-01-22
- Common Stock, par value $0.0001 per share: 21750 shares at $N/A (D)
- Convertible Notes: 21750 shares at $2.8 (D)

Inside Trans: JUPITER NEUROSCIENCES, INC. (JUNS) by Weis Holger (Unknown Title) on 2025-01-22
- Common Stock, par value $0.0001 per share: 10781 shares at $N/A (D)
- Convertible Notes: 10781 shares at $2.8 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -2439625.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.6944
Average Volume: 109491.48
30-Day High: 0.778
30-Day Low: 0.5314

[Detailed Financials: TTM 2024]
- Total Assets: $6,202,409.0
- Total Liabilities: $2,030,401.0
- Total Equity: $4,172,008.0
- Current Assets: $4,650,263.0
- Current Liabilities: $2,009,154.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.08

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0

[Detailed Financials: FY 2024]
- Total Assets: $6,202,409.0
- Total Liabilities: $2,030,401.0
- Total Equity: $4,172,008.0
- Current Assets: $4,650,263.0
- Current Liabilities: $2,009,154.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.08

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Jupiter Neurosciences (JUNS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Jupiter Neurosciences.

2) MARKET_SCORE[]
This conversation was initiated because JUNS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for JUNS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, JUNS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect JUNS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Jupiter Neurosciences.

11) ETHICAL_RATING[]
Rate Jupiter Neurosciences’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Jupiter Neurosciences.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

JUNS_IN_43 [2025-04-16 10:37:31 -0400] 126 Bytes | 29 tokens | Cum: 7732 tkns (96.65% of 8k)
==========================================================================

====================================
[2025-04-16 10:37:31] # Analysis Completed
Elapsed Time: 41.44 seconds